Skip to content

Analysis of therapeutic effect and related influencing factors of neoadjuvant chemotherapy in patients with poorly differentiated gastric adenocarcinoma

Analysis of therapeutic effect and related influencing factors of neoadjuvant chemotherapy in patients with poorly differentiated gastric adenocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096818
Enrollment
Unknown
Registered
2025-02-07
Start date
2025-02-28
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric adenocarcinoma

Interventions

Observation group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Gastric adenocarcinoma confirmed by gastroscopy biopsy (including papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma and signet ring cell carcinoma according to WHO classification); (2) Poorly differentiated; (3) The clinical stage was T2-4N-/+M0; (4) Patients received neoadjuvant chemotherapy before surgery; (5) The number of neoadjuvant chemotherapy cycles >=2; (6) Patients underwent radical gastrectomy (R0 resection) after neoadjuvant chemotherapy; (7) The age of patients ranged from 18 to 80 years old. (8) Complete clinicopathological data.

Exclusion criteria

Exclusion criteria: (1) Patients received radiotherapy, targeted therapy, and immunotherapy before surgery; (2) Patients diagnosed with other malignant tumors at the same time or with a history of other malignant tumors; (3) The patient was diagnosed with gastric stump cancer; (4) The patient had severe abnormalities of lung, heart, liver and kidney function. (5) Patients with esophageal or gastrointestinal perforation during chemotherapy; (6) Patients with M1 detected during operation; (7) Patients with M1 confirmed by postoperative pathology; (8) Missing clinical data.

Design outcomes

Primary

MeasureTime frame
Gender;Age;Baseline body mass index;Tumor size;Clinical T staging;Preoperative chemotherapy;Preoperative chemotherapy cycles;Gross classification of tumors;Lauren classification of tumors;Location of the tumor;Histologic type of tumor;

Countries

China

Contacts

Public ContactKun Yang

West China Hospital, Sichuan University

yangkun068@163.com+86 189 8060 6729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026